Vertaling van "granting of authorisations " (Nederlands → Frans) :

TERMINOLOGIE

syndroom van Grant
syndrome de Grant

IN-CONTEXT TRANSLATIONS

The Registration (marketing authorisation) department of the FAMHP is responsible for evaluating new applications and applications for changes to existing marketing authorisations (variations), with a view to grant the authorisation for marketing a medicine or health product.
The Registration (marketing authorisation) department of the FAMHP is responsible for evaluating new applications and applications for changes to existing marketing authorisations (variations), with a view to grant the authorisation for marketing a medicine or health product.

Unit II Unit II is responsible for: ●● The recognition of industrial pharmacists ●● The granting of authorisations for the manufacture, import, export, wholesale, distribution of medicines ●● Dealing with quality problems (RAS – Rapid
Unit II Unit II is responsible for: ●● The recognition of industrial pharmacists ●● The granting of authorisations for the manufacture, import, export, wholesale, distribution of medicines ●● Dealing with quality problems (RAS – Rapid

The FAMHP’s Marketing authorisation Department is responsible for evaluating new applications and requests for amendments to existing marketing authorisation (MA) with a view to granting authorisation for marketing a medicine or health product.
The FAMHP’s Marketing authorisation Department is responsible for evaluating new applications and requests for amendments to existing marketing authorisation (MA) with a view to granting authorisation for marketing a medicine or health product.

In addition to the daily activities (inspections, granting of licences/authorisations/certificates, RAS) the Production & Distribution Department also focused efforts in 2008 on gradually solving the backlog of Dutch language establishment applications and transfer applications for retail pharmacies. Additionally, the backlog in respect of raw materials used by retail pharmacies was also tackled.
In addition to the daily activities (inspections, granting of licences/authorisations/certificates, RAS) the Production & Distribution Department also focused efforts in 2008 on gradually solving the backlog of Dutch language establishment applications and transfer applications for retail pharmacies. Additionally, the backlog in respect of raw materials used by retail pharmacies was also tackled.

The Production & Distribution department of the FAMHP is responsible firstly for overseeing the conformity to current standards, guidelines and legal requirements for the manufacture, distribution and dispensing of medicines and health products and secondly for granting authorisations, recognitions and certificates, as well as for combating illegal practices and monitoring pharmacies.
The Production & Distribution department of the FAMHP is responsible firstly for overseeing the conformity to current standards, guidelines and legal requirements for the manufacture, distribution and dispensing of medicines and health products and secondly for granting authorisations, recognitions and certificates, as well as for combating illegal practices and monitoring pharmacies.

The “PRE pillar” monitors the development of medicines and health products until the point when the initial marketing authorisation (MA) is granted.
The “PRE pillar” monitors the development of medicines and health products until the point when the initial marketing authorisation (MA) is granted.

It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.
It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.